Tetrahydrocannabinol

Cannabix Quantifies Marijuana Breath Samples from Maryland Green Lab – Results Analyzed at North Louisiana Criminalistics Laboratory

Retrieved on: 
Thursday, January 18, 2024
Collection, Smoking, NCLC, OTC, BCU, Fig, Smoker, Laboratory, THC, Tetrahydrocannabinol, Paraffin wax

Breath samples taken on January 3, 2024 during the Maryland green lab held by the Montgomery County Police Department were shipped to the North Louisiana Criminalistics Laboratory (“NLCL”) (Fig.

Key Points: 
  • Breath samples taken on January 3, 2024 during the Maryland green lab held by the Montgomery County Police Department were shipped to the North Louisiana Criminalistics Laboratory (“NLCL”) (Fig.
  • The data collected from 11 volunteer subjects (10 smokers and 1 subject who consumed THC infused edibles) showed similar results to those achieved during past green lab studies.
  • Cannabix continues to test and develop its BCU and MS Breath Sampler to quantify delta-9 THC in human breath samples.
  • Cannabix scientists are using an internal standard to generate a calibration curve for THC quantification in breath samples.

Akanda Corp. Announces Signing of Option to Develop Canadian THC and CBD Farming Facility

Retrieved on: 
Wednesday, September 20, 2023
Professional Services, Alternative Medicine, Cannabis, Health, Finance, Natural Resources, International, WKN, Sale, CBD, THC, Drug, Oyster farming, Tetrahydrocannabinol, Hemp, Akanda

International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C.

Key Points: 
  • International medical cannabis company Akanda Corp. (“Akanda” or the “Company”) (NASDAQ: AKAN, WKN: A3DG83) announces that Akanda (the “Optionee” the “Company”) and 1107385 B.C.
  • LTD (the “Owner”) have agreed upon terms to purchase farming land and related operations and licenses.
  • The initial payment will be broken up into the First Option Payment, the Second Option Payment and the Third Option Payment, upon signing, 15 days after signing, 30 days after signing respectively.
  • The Company plans during this time period to develop Tetrahydrocannabinol (THC) and CBD facilities at this site.

The Now Corporation (OTC: NWPN) Acquires An Equity Stake In A Revolutionary Free Speech Social Media Company, MePeeps Inc.

Retrieved on: 
Thursday, August 11, 2022
Adoption, CEO, Advertising, GLOBE, Technology, Sale, Behavior, THC, Research, Hatred, Life, Apple, Marketing, PR, No, Education, TikTok, Trust, OTC, Safety, HTTP cookie, Software, CBD, Android, Social media, Privacy, Government, Big Tech, Freedom of speech, Now Corporation, Video game, Public relations, Instagram, Corporation, Tetrahydrocannabinol

In 2020, social media ads spent stood at approximately 132 billion U.S. dollars, with spending expected to surpass the 200-billion-dollar mark by 2024.

Key Points: 
  • In 2020, social media ads spent stood at approximately 132 billion U.S. dollars, with spending expected to surpass the 200-billion-dollar mark by 2024.
  • And while the U.S. remains the largest social media ad market globally, marketers from other countries are also jumping on the social media train.
  • Unlike other Internet social media platforms, MePeeps has No tracking, No spam, No direct target advertisement and No Cookies stored on users devices.
  • He continues: Although MePeeps allows for Free Speech, we are not allowing, hate, obscenity, harassment, or misinformation of any sort.

GTR Unlocks The Secrets Of Delta-9 THC Modulation In Cannabis And Hemp

Retrieved on: 
Thursday, June 23, 2022
Texas A&M AgriLife Research, Tetrahydrocannabinol, Genomics, Regeneration, Genetics, Biotechnology, Mechanics, Plant, Research, Living Together, Growing Together, Disease, THC, Gene editing, Cannabis, Farmer, GTR, Partnership, Cannabidiol, Soybean, Face, Risk, Oil, Agriculture, Drug, CBD

FORT WAYNE, Ind., June 23, 2022 /PRNewswire-PRWeb/ -- Growing Together Research Inc. (GTR), a U.S. biotechnology company, today announced expanded research and product development capabilities to modulate the expression of Delta-9-tetrahydrocannabinol (THC) in C. sativa (Cannabis and Hemp).

Key Points: 
  • Earlier this year, GTR and Texas A&M AgriLife Research revealed its partnership had achieved the first known stable transformation and regeneration of multiple THC-free hemp cultivars.
  • Based on its demonstrated ability to turn "down" or "off" the genes coding for THC expression, now GTR is applying the same techniques to turn THC expression "up."
  • GTR will soon commence an effort in collaboration with Canada-based academic and commercial partners to create a cannabis cultivar with enhanced expression of THC.
  • "Understanding the mechanics of the THC pathway are perhaps the most important component of truly unlocking the promise of cannabis and hemp," said Sam Proctor, chief executive officer of GTR.

The Now Corporation (OTC: NWPN) Acquires an Equity Stake In Enhanced Premium Water Brand, CellDration™

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Now Corporation, Health, Â, CBD, Investment, Education, Environment, Plastic, THC, OTC Markets Group, Black History Month, News, Drink, Patent, Research, Bottled water, Tetrahydrocannabinol, Corporation

Both companies will collaborate on the development of various line extensions, including flavored & CBD infused beverages.

Key Points: 
  • Both companies will collaborate on the development of various line extensions, including flavored & CBD infused beverages.
  • Its Black History Month, two African-American, majority owned companies are partnering for good health, a healthier lifestyle and to successfully compete in the flavored and infused water market.
  • Furthermore, this investment will allow synergies with CellDration regarding expertise and a platform to launch our infused beverages in addition to our psychoactive infused beverage products, once our patent is approved for its delivery.
  • said The Now Corporation CEO, Ken Williams.

IGC Reports Financial Results for the December 31, 2021 Quarter

Retrieved on: 
Thursday, February 10, 2022
Biotechnology, Pharmaceutical, Health, Other Health, List of life sciences, NYSE, Patient, Infrastructure, Dementia, Depression, Company, Holi, General officer, SEC, Research and development, Congress, R, Report, Safety, Board of directors, GMP, Anxiety, In Defense of Global Capitalism, Compte rendu, Tetrahydrocannabinol, Administration, FDA, Sale, Board, Agitation, Risk, Failure, IGC, Patent, Hand, Research, NPS, COVID-19, SG, Caregiver, THC, Pharmaceutical industry

India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ending December 31, 2021 quarter three of the Companys 2022 fiscal year.

Key Points: 
  • India Globalization Capital, Inc. (NYSE American: IGC) announces its financial results for the three months ending December 31, 2021 quarter three of the Companys 2022 fiscal year.
  • As previously reported, the trial analyzed the safety and efficacy of different dosages, and the results were encouraging.
  • The Infrastructure segment, which includes a construction contract, was $8 thousand in the quarter, relative to $52 thousand the year prior.
  • IGC incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Reports on Form 10-K filed with the SEC on June 14, 2021, and Quarterly Report on Form 10-Q, filed with the SEC on August 11, 2021, October 29, 2021, and February 10, 2022.

Sugarmade Signs Binding LOI to Enter Rare Cannabinoid Market via License Agreement for Patented THC-V Rich Chemovars

Retrieved on: 
Monday, January 24, 2022
Forward-looking statement, Nature, 2-Arachidonoylglycerol, Appetite, Cell, Cannabis, THCA, CEO, Hunger, GLOBE, CB2, Cannabinoid, Obesity, NUG, Bacteria, OTC Markets Group, THC, British Journal of Pharmacology, Smoking, Biomass, Private Securities Litigation Reform Act, Company, Ligand, Patent, Laboratory, Metabolic syndrome, LOI, CB1, Drug, Viticulture, Oil, Tetrahydrocannabivarin, Tetrahydrocannabinol

While THC-V is sometimes referred to as a rare cannabinoid, we believe the term no longer applies relative to our planned cultivation effort using GenCanns Chemovars, commented Jimmy Chan, CEO of Sugarmade.

Key Points: 
  • While THC-V is sometimes referred to as a rare cannabinoid, we believe the term no longer applies relative to our planned cultivation effort using GenCanns Chemovars, commented Jimmy Chan, CEO of Sugarmade.
  • Sugarmade plans to make a substantial commitment to bring products based on THC-V to the California market and perhaps to other states in the future.
  • Sugarmade plans to utilize the THC-V rich biomass in a series of products it plans to introduce to the licensed California marketplace.
  • Sugarmade is also the first licensee of the unique and patented GenCann, Inc. THC-V rich chemovars.

USP Cannabis Expert Panel Identifies Public Health Issues Associated with Delta-8 THC Products & Offers Recommendations

Retrieved on: 
Thursday, December 2, 2021
United States Pharmacopeia, CEO, Field, Industry, Tetrahydrocannabinol, THC, Health, Dietary supplement, ASTM International, Laboratory, Safety, Research, Consumer, Organization, Criticism of the Food and Drug Administration, USP, FDA, Public health, Science, CDC, Multimedia, Internet, Method, Food, Cannabinoid, ASTM, Medical device, Pharmaceutical industry

Depending on how the products are produced, unknown impurities may be introduced, including minor and synthetic cannabinoid compounds that are not naturally occurring in cannabis," explains Dr. Ikhlas Khan, Chairman of USP's Expert Panel on cannabis.

Key Points: 
  • Depending on how the products are produced, unknown impurities may be introduced, including minor and synthetic cannabinoid compounds that are not naturally occurring in cannabis," explains Dr. Ikhlas Khan, Chairman of USP's Expert Panel on cannabis.
  • USP's commentary, It's time to hold cannabinoid products to the highest standard: USP Cannabis Panel statement on Delta8-THC, looks at a number of issues surrounding the controversies of delta-8 THC and recommends:
    Clinical research into the investigation of minor cannabinoids, such as delta-8 THC.
  • By using public quality standards, we can help in controlling the quality of the products and set appropriate limits for impurities.
  • For more information about USP's work and their cannabis reference standards to protect public health and promote sound research in the cannabis industry, go to www.usp.org/cannabis .

Phase 1 Clinical Trial Data Indicate IGC’s THC-based Investigational New Drug May Reduce Symptoms of Dementia in Alzheimer’s Patients

Retrieved on: 
Thursday, December 2, 2021
Alternative Medicine, Mental Health, Health, Other Health, Clinical Trials, Biotechnology, 8-K, Patient, Caregiver, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, PMS, Anxiety, Cognition, Safety, Risk, Tetrahydrocannabinol, NYSE, Dysmenorrhea, Dementia, THC, Clinical trial, SEC, Belligerent, Nature, COVID-19, Annual report, Securities Exchange Act of 1934, Agitation, IGC, Patent, Screaming, Depression, FDA, Report, Compte rendu, Crying, Failure, Food, Aggression, Quality of life, Pharmaceutical industry

The investigational new drug, IGC-AD1, is IGCs proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimers disease.

Key Points: 
  • The investigational new drug, IGC-AD1, is IGCs proprietary Tetrahydrocannabinol (THC)-based candidate designed to treat certain symptoms of Alzheimers disease.
  • Currently, there is no FDA-approved medication to alleviate symptoms of dementia, such as agitation, due to Alzheimers disease.
  • To the best of our knowledge, this is the first human clinical trial combining low doses of THC with another molecule to treat symptoms of dementia in Alzheimers patients.
  • The life sciences business recently completed the first safety and tolerability clinical trial to treat symptoms of Alzheimers patients using a THC-based investigational new drug.

SwabTek™ being deployed to identify Hemp vs. Marijuana

Retrieved on: 
Thursday, August 5, 2021
Tetrahydrocannabinol, Narcotic, SAN, Color, Oil, Gel, Total, Multimedia, Private sector, Organization, Cannabis, Drug, Medicinal plants

The test was designed to meet the demand of law enforcement organizations to be able to discern between hemp and marijuana while in the field.

Key Points: 
  • The test was designed to meet the demand of law enforcement organizations to be able to discern between hemp and marijuana while in the field.
  • The THC test kit is the latest entry in SwabTek's portfolio of industry-leading tools for explosives and narcotics detection.
  • The SwabTek THC test kit is designed to be used in analyzing the concentration of Total THC present in a given sample.
  • THC is the psychoactive component of cannabis, and its concentration marks the difference between hemp (0.3%).